
Oncologist discuss the possibility of earlier-line CAR T-cell therapies in MM.
Oncologist discuss the possibility of earlier-line CAR T-cell therapies in MM.
Luciano J. Costa, MD, PhD, discusses the promising role of CAR T-cell therapy in relapsed/refractory multiple myeloma.
Luciano J. Costa, MD, PhD, discusses remaining challenges with investigational CAR T-cell therapies in relapsed/refractory multiple myeloma.
Luciano J. Costa, MD, PhD, associate professor of medicine, Blood and Marrow Transplantation and Cell Therapy Program, University of Alabama at Birmingham School of Medicine, discusses phase II findings with the triplet regimen of venetoclax (Venclexta), carfilzomib (Kyprolis), and dexamethasone in patients with relapsed/refractory multiple myeloma. Costa shared this insight in an interview with OncLive during the 2018 ASCO Annual Meeting.
Published: August 16th 2024 | Updated: August 19th 2024
Published: March 18th 2024 | Updated: June 3rd 2024
Published: December 7th 2024 | Updated:
Published: December 12th 2022 | Updated:
Published: July 14th 2024 | Updated:
Published: May 18th 2023 | Updated: